First-Line Maintenance Therapy with Avelumab Show Significantly Prolonged OS and PFS in Patients with Advanced Urothelial Cancer with Low Tumor Burden
Dr. Joaquim Bellmunt from the Dana-Farber Cancer Institute, Harvard Medical School, summarizes findings from the JAVELIN 100 study presented at ASCO 2024. The study evaluated the efficacy of maintenance avelumab plus Best Supportive Care versus Best Supportive Care alone in patients with advanced urothelial cancer who had low tumor burden. The study show significantly prolonged OS and PFS and manageable toxicity for those patients receiving avelumab
